HOME >> MEDICINE >> NEWS
Polverini to receive IADR Oral Medicine and Pathology Award

Dr. Peter Polverini, Professor and Dean of the University of Michigan School of Dentistry (Ann Arbor), has been named the 2006 recipient of the Oral Medicine and Pathology Research Award, conferred by the International Association for Dental Research (IADR), convening here today for its 84th General Session.

A native of Everett, Massachusetts, Dr. Polverini was educated at Marquette University School of Dentistry (Milwaukee, WI), with post-graduate studies at the Harvard Medical School and the Harvard School of Dental Medicine. He has been honored many times for his teaching and research in oral pathology, including the award of the Donald A. Kerr Endowed Professorship at the University of Michigan, and is a Fellow of the American College of Dentists. He has served as member and chair of many NIH Study Sections and served on the editorial board of the International Journal of Oral Biology and the Journal of Oral Medicine and Pathology. He has published extensively on his research into angiogenesis and oral cancer.

The IADR Oral Medicine and Pathology Research Award is supported by Sunstar Butler and consists of a cash prize and a plaque. It is one of 15 Distinguished Scientist Awards given annually by the IADR.

Dr. Polverini receives his award today during the Opening Ceremonies of the IADR's 84th General Session.


'"/>

Contact: Linda Hemphill
lhemphill@iadr.org
International & American Association for Dental Research
28-Jun-2006


Page: 1

Related medicine news :

1. Indiana University Imaging Center receives $6M grant for kidney research
2. FPG receives $8 million for autism research
3. USC and Childrens Hospital Los Angeles both receive grants for stem cell facilities
4. Tony Hunter receives Robert. J. and Claire Pasarow Award for Cancer Research
5. Boston University School of Medicine faculty member receives honorary degree from alma mater
6. UCLA Stroke Center receives American Stroke Associations Initial Achievement Award
7. San Francisco VA researcher receives top Veterans Affairs award
8. RAND study finds women with heart disease and diabetes less likely to receive proper care
9. Ronald W. Busuttil receives American Surgical Associations highest honor
10. Menzies School of Health Research receives $5.3 million in Federal Budget
11. Who receives a kidney transplant first?

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Polverini receive IADR Oral Medicine and Pathology Award

(Date:9/4/2015)... ... , ... Mike Day, a former Navy SEAL who was shot 27 times ... in Kona on October 10th. , Mike is running the race to raise awareness ... the cutting-edge treatments that restore their quality of life. More than 300,000 ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Having access to ... has led to an increasing amount of unnecessary emergency room visits which affects hospitals’ ... taxes the country’s health bill. Fortunately, a solution to alleviate this problem has recently ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... are prophetic details involving the Pope’s upcoming trip to the United States. , Yisrayl lays ... his role with the Vatican and society is. Yisrayl also provides the meaning of his ...
(Date:9/3/2015)... ... ... While bariatric surgeon Michael Feiz, M.D., F.A.C.S. notes that he advises all ... some patients have been recently asking further questions relating to the best way to ... surgery that should be followed in the days prior to the procedure, Dr. Feiz ...
(Date:9/3/2015)... ... 03, 2015 , ... The Oregon Collaborative for Integrative Medicine ... & Medicine (AIHM) Interprofessional Fellowship in Integrative Health & Medicine. The AIHM Fellowship ... renowned educator, physician and thought leader in integrative medicine. This is the first ...
Breaking Medicine News(10 mins):Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 2Health News:Oregon Collaborative for Integrative Medicine Partners with AIHM on First Interprofessional Fellowship 3
(Date:9/4/2015)... LONDON , September 4, 2015 ... & Vaccines  Allergic Rhinitis drugs ... revenues Where is the market for allergic ... this market? Visiongain ,s new report shows you ... opportunities and prospects. Our 326 page report ...
(Date:9/4/2015)... Sep. 04, 2015 Research and ... "Investigation Report on China,s Sodium Ibandronate Market, 2010-2019" ... in the clinic under the trade name of Bondronat in ... in 1996, sodium ibandronate was approved by the FDA ... osteoporosis under the trade name of Boniva. However, since drug ...
(Date:9/4/2015)... , September 4, 2015 ... today announces that Hutchison MediPharma Limited ("HMP"), its ... in the second proof-of-concept ("POC") trial of fruquintinib ... cancer ("NSCLC") in China . ... succeeded in meeting the primary efficacy endpoint of ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
Cached News: